Massimo Caracciolo Sebastiano Macheda Demetrio Labate Marco Tescione Stefano La Scala Eugenio Vadalà Rosalba Squillaci Francesco D'Aleo Antonella Morabito Cristina Garreffa Maria Concetta Marciano Esther N Oliva
10.3389/fimmu.2020.01942
Front Immunol
2020 Aug 25;11:1942.
covid-19 il-1 il-6 sars-cov-2 acute respiratory distress syndrome canakinumab cytokine storm natural killer
CC BY
https://pubmed.ncbi.nlm.nih.gov/32983123/
Antibodies, Monoclonal, Humanized / therapeutic use Betacoronavirus Coronavirus Infections / drug therapy Pneumonia, Viral / drug therapy Respiratory Distress Syndrome / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use Betacoronavirus Coronavirus Infections / drug therapy Pneumonia, Viral / drug therapy Respiratory Distress Syndrome / drug therapy Case Reports Aged, 80 and over Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / pharmacology CD56 Antigen / metabolism COVID-19 COVID-19 Drug Treatment Coronavirus Infections / virology Fatal Outcome Humans Interleukin-1beta / antagonists & inhibitors Interleukin-6 / blood Killer Cells, Natural / immunology Male Pandemics Pneumonia, Viral / virology Respiratory Distress Syndrome / virology SARS-CoV-2 Severity of Illness Index Antibodies, Monoclonal, Humanized CD56 Antigen IL1B protein, human IL6 protein, human Interleukin-1beta Interleukin-6 NCAM1 protein, human canakinumab
PMC7477112
32983123
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
2020